Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
PHASE3
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone th...
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
PHASE3
A randomized, double-blind, multicenter phase III clinical study to evaluat...
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
PHASE2
A study to evaluate the efficacy and safety of triplet combination of inavo...
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
PHASE2
This is a multicenter, randomized, double-blind study of fulvestrant plus e...
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
PHASE3
The purpose of this study is to find out whether a new drug, Ipatasertib, c...
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
PHASE3
This study was a multi-center, randomized, double-blind, placebo controlled...
Status
Completed
Location
University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2)